These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 23045273

  • 41. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
    Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T.
    Int J Oncol; 2015 Feb; 46(2):497-504. PubMed ID: 25532027
    [Abstract] [Full Text] [Related]

  • 42. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL.
    Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
    [Abstract] [Full Text] [Related]

  • 43. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [Abstract] [Full Text] [Related]

  • 44. Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
    Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, Kuwano M, Ono M.
    Cancer Res; 2013 Oct 15; 73(20):6243-53. PubMed ID: 23872583
    [Abstract] [Full Text] [Related]

  • 45. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S, Sasaki T, Minami Y, Ohsaki Y.
    J Thorac Oncol; 2012 Jan 15; 7(1):49-56. PubMed ID: 22089115
    [Abstract] [Full Text] [Related]

  • 46. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Park JH, Choi YJ, Kim SY, Lee JE, Sung KJ, Park S, Kim WS, Song JS, Choi CM, Sung YH, Rho JK, Lee JC.
    Oncotarget; 2016 Apr 19; 7(16):22005-15. PubMed ID: 26980747
    [Abstract] [Full Text] [Related]

  • 47. EGFR T790M mutation: a double role in lung cancer cell survival?
    Suda K, Onozato R, Yatabe Y, Mitsudomi T.
    J Thorac Oncol; 2009 Jan 19; 4(1):1-4. PubMed ID: 19096299
    [Abstract] [Full Text] [Related]

  • 48. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
    Song X, Liu X, Ding X.
    J Mol Recognit; 2017 Apr 19; 30(4):. PubMed ID: 27891677
    [Abstract] [Full Text] [Related]

  • 49. EGFR T790M resistance mutation in non small-cell lung carcinoma.
    Denis MG, Vallée A, Théoleyre S.
    Clin Chim Acta; 2015 Apr 15; 444():81-5. PubMed ID: 25668228
    [Abstract] [Full Text] [Related]

  • 50. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, Mitsudomi T.
    Sci Rep; 2015 Sep 24; 5():14447. PubMed ID: 26400668
    [Abstract] [Full Text] [Related]

  • 51. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M, Kiura K.
    Mol Cancer Ther; 2011 Sep 24; 10(9):1720-7. PubMed ID: 21712475
    [Abstract] [Full Text] [Related]

  • 52. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, Kimura M, Oba S, Kato K.
    Lung Cancer; 2016 Apr 24; 94():68-73. PubMed ID: 26973209
    [Abstract] [Full Text] [Related]

  • 53. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
    Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA.
    Nat Med; 2016 Mar 24; 22(3):262-9. PubMed ID: 26828195
    [Abstract] [Full Text] [Related]

  • 54. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
    Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA.
    Clin Cancer Res; 2015 Sep 01; 21(17):3924-33. PubMed ID: 25964297
    [Abstract] [Full Text] [Related]

  • 55. Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.
    Lim SM, Jeong Y, Hong S.
    Future Med Chem; 2016 May 01; 8(8):853-78. PubMed ID: 27195594
    [Abstract] [Full Text] [Related]

  • 56. A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance.
    Taube E, Jokinen E, Koivunen P, Koivunen JP.
    Int J Cancer; 2012 Aug 15; 131(4):970-9. PubMed ID: 21953013
    [Abstract] [Full Text] [Related]

  • 57. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
    Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV.
    Cancer Discov; 2015 Jul 15; 5(7):713-22. PubMed ID: 25934077
    [Abstract] [Full Text] [Related]

  • 58. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
    Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W.
    PLoS One; 2007 Aug 29; 2(8):e810. PubMed ID: 17726540
    [Abstract] [Full Text] [Related]

  • 59. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
    Qin M, Wang T, Xu B, Ma Z, Jiang N, Xie H, Gong P, Zhao Y.
    Eur J Med Chem; 2015 Nov 02; 104():115-26. PubMed ID: 26451770
    [Abstract] [Full Text] [Related]

  • 60. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y, Song Z, Jin Y, Tang Z, Kang J, Ma X.
    Molecules; 2016 Nov 02; 21(11):. PubMed ID: 27827863
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.